Relevance of glucagon-like peptide-1 signalling in health There is evidence to suggest that specific enterohormones administered at physiological concentrations can influence the appetite of rodents and human subjects (for a review, see Murphy & Bloom (Reference Murphy and Bloom6) )
Nat Sci Sleep.5:27-35

For patients with type 2 diabetes and Hashimoto's, options include: Semaglutide (Ozempic) : Once-weekly injection with robust efficacy for glycemic control, weight loss, and cardiovascular risk reduction Semaglutide (Rybelsus) : Oral daily tablet requiring careful timing with levothyroxine Dulaglutide (Trulicity) : Once-weekly injection with established cardiovascular benefits Liraglutide (Victoza) : Daily injection with cardiovascular risk reduction and extensive long-term safety data Tirzepatide (Mounjaro) : Once-weekly injection combining GLP-1 and GIP receptor agonism, showing superior efficacy in clinical trials For patients with obesity and Hashimoto's, FDA-approved options include: Semaglutide (Wegovy) : Once-weekly injection at higher doses than Ozempic Liraglutide (Saxenda) : Daily injection Tirzepatide (Zepbound) : Once-weekly injection with significant weight loss efficacy The presence of Hashimoto's thyroiditis does not inherently favor one GLP-1 medication over another

This isn't a fad it's a structured program with consultation, lab review, dose titration, and check-ins
If forced to rank the three by how much confident language they can support, the honest ranking runs opposite to complexity: the simplest blend permits the least-overreaching claims, and even it permits very little
Participants were randomized 1:1, with blinded raters assessing depressive severity using the 17-item Hamilton Depression Rating Scale (HAMD-17) at baseline and Day 29